Benutzer: Gast  Login
Titel:

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.

Dokumenttyp:
Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article
Autor(en):
Trøseid, Marius; Arribas, José R; Assoumou, Lambert; Holten, Aleksander Rygh; Poissy, Julien; Terzić, Vida; Mazzaferri, Fulvia; Baño, Jesús Rodríguez; Eustace, Joe; Hites, Maya; Joannidis, Michael; Paiva, José-Artur; Reuter, Jean; Püntmann, Isabel; Patrick-Brown, Thale D J H; Westerheim, Elin; Nezvalova-Henriksen, Katerina; Beniguel, Lydie; Dahl, Tuva Børresdatter; Bouscambert, Maude; Halanova, Monika; Péterfi, Zoltán; Tsiodras, Sotirios; Rezek, Michael; Briel, Matthias; Ünal, Serhat; Schlegel,...     »
Abstract:
BACKGROUND: Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. METHODS: Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients with severe/critical COVID-19 were randomised to Baricitinib 4 mg once daily or plac...     »
Zeitschriftentitel:
Crit Care
Jahr:
2023
Band / Volume:
27
Heft / Issue:
1
Volltext / DOI:
doi:10.1186/s13054-022-04205-8
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/36627655
Print-ISSN:
1466-609X
TUM Einrichtung:
Klinik für Anästhesiologie (DHM)
 BibTeX